Genor Biopharma closes USD160m Series B Round led by Hillhouse Capital

Genor Biopharma has completed a USD160 million Series B financing round led by existing investor Hillhouse Capital, with participation from new investors Temasek, CR-CP Life Science Fund, Haitong Kaiyuan Investment, and Cavenham PE.

Genor Biopharma has completed a USD160 million Series B financing round led by existing investor Hillhouse Capital, with participation from new investors Temasek, CR-CP Life Science Fund, Haitong Kaiyuan Investment, and Cavenham PE.

Proceeds from this financing round will be used for the promotion of clinical projects in existing product pipeline, the development of early-stage innovative drugs, potential domestic and foreign strategic cooperation, and preparation for the commercialization of its products in the later stages of development.

Established in December 2007, Genor Biopharma is an R&D-driven innovative biopharmaceutical company. It is committed to providing accessible drugs to patients who do not meet the needs of treatment. The company’s product pipeline is mainly centered in the field of tumors and other major diseases, and has established a series of mature technology platforms in antibody drug research, development and manufacturing to serve Chinese and global patients.

To date, Genor Biopharma has more than 10 products in development, 10 of which have entered the clinical development stage.

Genor Biopharma has set up three offices and industrial bases in Shanghai, Yunnan Province and Beijing. The company currently has more than 400 employees, of which 80% are scientific researchers. The company’s management team has more than 20 years of industrial experience in global biopharmaceutical companies such as Pfizer, Amgen and AbbVie.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/02/genor-biopharma-closes-usd160m-series-b-round-led-by-hillhouse-capital/.

Leave a Reply

Please Login to Comment